Biography:

Thomas J Lewis is a Medical Scientist. He holds a PhD in Chemistry from MIT and certification from the Harvard School of Public Health. He is an entrepreneur and healthcare professional with expertise in toxic substances, drug development, biotechnology, health technology and medical protocol development. For the past decades, he  has worked closely with senior researchers and clinicians at Harvard Medical School and has developed a program for chronic disease root cause prevention, screening, diagnosis and treatment. Alzheimer’s disease and the most serious eye diseases, macular degeneration and glaucoma have been a particular focus. He has opened the first-of-its-kind Alzheimer’s prevention, screening, early detection and treatment centre in the Orlando, Florida area in 2014. He works closely with Dr. Clement Trempe, 41years at Harvard Medical School who is one of few doctors in the world who treats chronic eye diseases as systemic inflammatory conditions – and reverses these conditions with great success. It was through this work that Dr Trempe developed his protocol for diagnosing, treating and reversing Alzheimer’s disease that is now an integral part of the Health Revival offering.

Abstract:

Critical to broad acceptance of newer technologies is an understanding of the causes behind both success and failure of treatments. As humans age, their immune system undergoes immunosenescence. The progressive deterioration of the immune system is one contributing factor to the characteristic decline in stem cell activity that also accompanies aging, at least with regard to certain types of stem cells. Underlying low-grade chronic disease and accompanying immune activation and inflammation also drive senescence processes and concomitantly impacts stem cell efficacy. It’s well established that inflammatory sites and an inflammatory milieu are hostile towards the survival of transplanted cells. Practitioners who apply stem cell therapy have a significant opportunity to take a leading role in understanding and reversing accelerated aging. Stem cell therapy, to be most impactful, should be delivered along with anti-inflammatory strategies. Key to this approach is understanding the immune system/inflammatory status of each patient. Presented here is a novel Harvard Medical School and MIT developed a systems approach to accurately and precisely measure immune and chronic inflammatory status. The Chronic Disease Assessment™ and Chronic Disease  Temperature™ provide a subjective and objective easure of immune status and  include a path to reducing inflammation. The eye plays an important role in this program. Cataract, for example, is a sign of systemic inflammation, stem cells disease, high cardiovascular risk, and early mortality. The lens of the eye uniquely acts like a single large stem cell. The connection between life risks, biomarkers and eye pathologies will be discussed in the context of a holistic approach to successful stem cell therapy.

Biography:

Magnus S Magnusson, Research Professor. PhD in 1983, University of Copenhagen. He is the author of the T-pattern and the T-systeem model, initially focused on the real-time organization of behavior, that forms the basis of his corresponding dedicated pattern detection software THEMEtm. He has co-directed a two year DNA analysis project. He has published numerous papers and given invited talks and keynotes at international mathematical, neuroscience, proteomics, A.I., bioinformatics and science of religion conferences and at leading universities in Europe, USA, and Japan. Deputy Director 1983-1988, Anthropology, National Museum of Natural History, Paris. Then he has repeatedly invited temporary university Professor in psychology and ethology (biology of behavior) at the University of Paris (V, VIII & XIII). Since 1991, founder and director of the Human Behavior Laboratory, University of Iceland. He Works in formalized collaboration between now 32 European and American universities based on “Magnusson’s analytical model” initiated at University René Descartes Paris V, Sorbonne, in 1995.

Abstract:

This talk concerns spatial and temporal self-similarity across more than nine orders of magnitude, implicating a self-similar fractal-like pattern, called T-pattern, a natural or pseudo-fractal pattern, recurring with statistically significant translation symmetry. The T-pattern, the core of the T-system of structural concepts is a result of an ethological (i.e. biology of behavior) project started in the early 1970’s primarily on social interaction and organization in social insects and primates including humans inspired mainly by the ethological work of Lorenz, von Frisch and Tinbergen for which they shared a Nobel Prize in Medicine or Physiology in 1973. Notably, in this context, their smallest subjects were social insects and thus no consideration of self-similarity. The present project has focused on developing time pattern definitions with corresponding detection algorithms resulting in the T-pattern type and the dedicated THEME software, which has allowed their abundant detection in many kinds of animal and human behavior and interactions and later in neuronal interactions within living brains, thus showing T-patterned self-similarity of temporal interaction between and within brains. The RNA world invented its evolving external memory as the purely informational giant T-patterned DNA strings and now there is only a DNA world. Similarly, billions of years later, humans invented their evolving external memory as the purely informational T-patterned strings (T-strings) of written language that have made possible, in a biological eye-blink, the development of modern science and technology and the creation of extremely populous and complex human mass-societies, the only mass-societies among large-brained animals and recent discoveries of the nanoworld of cells and molecules. Protein and human mass-societies seem to be the only ones using such durable giant T-strings external to their citizens. Human and protein mass-societies create their specialized citizens using various sub-sections of such T-strings, not found, notably in social insect societies. Extensive temporal and spatial self-similar patterning thus seems to exist in form and function from nano to human temporal and spatial scales suggesting structural, functional and organizational principles.

Biography:

Jack A Coleman has earned his MD from the University of Cincinnati College of medicine in 1979, did his internship and General Surgery requirement at Cincinnati general Hospital and Residency in Otolaryngology – Head and Neck Surgery at eh University of Pittsburgh Eye and ear Hospital as well as a fellowship in Cosmetic and general Plastic Surgery at eh English Plastic and Cosmetic Surgery Cenrter. He has been an Assistant Professor at Vanderbilt University and Clinical Assistant Professor irginia Medical School. Currently he is the Senior Medical Director of the Lung Health Institute. He has published 24 articles in refereed journals, many book chapters and 5 books reklated to his various interests in medicine as well as being a national and international guest lecturer.

Abstract:

Bronchiectasis is a chronic disease of the lungs that results most commonly from an infectious process. There is often differentiation between Cystic Fibrosis related bronchiectasis caused by a genetic defect and non-Cystic Fibrosis related bronchiectasis. In this presentation, we will be discussing non-Cystic Fibrosis related bronchiectasis and will refer to it as simply bronchiectasis. The infections result in abnormal distortion of the bronchi consisting of dilation. This results in colonization by bacteria and chronic inflammation of the airways causing cough, purulent sputum, hemoptysis, dyspnea, chest pain fever, weakness and weight loss. Exacerbations have been common in the past but less so with more aggressive antibiotic therapy. Decreasing lung function results in eventual death with rates varying with reports from 58% 4year survival to 81% at 14 years. In this study, we have attempted to try and control or alter the rate of progress of the disease and improve the patient’s quality of life by utilizing Regenerative Medicine methods to try and control the damaging inflammatory process within the lungs. Patients underwent cellular therapy with their own cells harvested from peripheral blood or bone marrow along with platelet-rich plasma. This was done as a standardized protocol in an office setting. Safety and response rate for the protocol used has previously been reported. At the time of initial evaluation, PFT and COPD Assessment Test (CAT) studies were administered as well as severity scores for the disease. Follow up studies at 3 months were also done and will be presented here.

Biography:

Dr. Jonathan Brenner, PhD has been selfemployed since he went to college and successfully ran several businesses in the U.S and abroad. Jonathan managed for 10 years the investment banking side of a Broker-Dealer, financing and guiding mostly medical-and biotech companies, orchestrating spin-offs and taking companies public, as well as negotiating and executing JVs and M&A of those companies with Fortune 100 and Fortune 500 companies.

He also was a Consultant under President Bush’s initiated Help America Vote Act as

well as under President Bush’s initiated No Child Left Behind Act. Besides being the Owner and Chief Executive Officer of MEDICUS, LLC, a Company dedicated to provide Physicians

with homeopathic- and bio-identical prescription medications, and MEDICUS Health & Vitality Clinics, both with Headquarters in Tampa, FL, Jonathan is the co-owner of EPR-Technologies, Inc., a Company that has received approximately $14,000,000.00 in Grants from the U.S. Army and $2,500,000.00 in Grants from the U.S. Navy. EPR is a spinoff from the Safar Center for Resuscitation Research, University of Pittsburgh School of Medicine. EPR has a medical device that has proven to save lives through Rapid Profound Hypothermia, in order “to save brains too good to die”.

Abstract:

In 2010 President Barack Obama signed the reversal of the ban on Stem Cell research in the United States and permitted Federal funding of Stem Cell research for 21 Stem Cell lines (Nature 473, 15 (2011)). Since then private funding and industry sponsored clinical studies and clinical use of Stem cells has accelerated and reached the level in which the body of clinical evidence far surpasses the available clinical trials and begs the creation of FDA directed regulation, and granting of Investigational New Drug licenses to further the progress of formal Randomized Prospective Clinical Trials (FDA Clinical Trials.gov). The guidance of the FDA commissioner, Scott Gothlieb, MD in his paper with Peter Marks, MD, PhD ( NEJM 378;10 – 3/8/18) has provided a pathway to the future of stem cell clinical investigation and use once the three year moratorium on regulatory enforcement has expired. This author presents a ten year clinical experience with clinical stem cell administration and discusses the results with treatment of various clinical indications as well as formal clinical studies currently being conducted in the US and other countries.

Biography:

Dr. Naidoo is a physician scientist with a doctorate in Medicine from Yale University, he also holds biomedical engineering degrees and completed Orthopedic Surgical training at Albert Einstein College of Medicine. After a career teaching orthopedic surgery in NYC at Mt Sinai School of Medicine, Dr. Naidoo relocated to Florida where he established an orthopedic practice in Palm Beach and Broward counties. He joined MEDICUS Health & Vitality Clinics in 2018 and was promoted to Chief Medical Officer of the Regenerative Division beginning March 2019. With attention to detail and a profound understanding of how the body moves and functions over time, Dr. Naidoo is able to help his patients heal from their injuries and return to lifestyles they once enjoyed. Dr. Naidoo is a native of South Africa and in his early years proudly served the revolutionary army of Nelson Mandela in South Africa’s struggle for freedom.

Abstract:

In 2010 President Barack Obama signed the reversal of the ban on Stem Cell research in the United States and permitted Federal funding of Stem Cell research for 21 Stem Cell lines (Nature 473, 15 (2011)). Since then private funding and industry sponsored clinical studies and clinical use of Stem cells has accelerated and reached the level in which the body of clinical evidence far surpasses the available clinical trials and begs the creation of FDA directed regulation, and granting of Investigational New Drug licenses to further the progress of formal Randomized Prospective Clinical Trials (FDA Clinical Trials.gov). The guidance of the FDA commissioner, Scott Gothlieb, MD in his paper with Peter Marks, MD, PhD ( NEJM 378;10 – 3/8/18) has provided a pathway to the future of stem cell clinical investigation and use once the three year moratorium on regulatory enforcement has expired. This author presents a ten year clinical experience with clinical stem cell administration and discusses the results with treatment of various clinical indications as well as formal clinical studies currently being conducted in the US and other countries.